Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences
November 08, 2012 16:30 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports Third Quarter 2012 Financial Results
November 07, 2012 08:00 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Date of Third Quarter 2012 Financial Results Conference Call
October 18, 2012 16:48 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Oct. 18, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences
August 30, 2012 17:00 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta to Present at the Canaccord Genuity 32nd Annual Growth Conference
August 08, 2012 16:01 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Acknowledges Federal Circuit Opinion Supporting Order Issued January 26, 2012 in Ongoing Suit Against Amphastar Pharmaceuticals and Watson Pharmaceuticals
August 03, 2012 16:56 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Aug. 3, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports Second Quarter 2012 Financial Results
August 02, 2012 08:00 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Date of Second Quarter 2012 Financial Results Conference Call
July 16, 2012 08:00 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., July 16, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
First Patient Dosed With M402 in Phase 1/2 Clinical Trial in Metastatic Pancreatic Cancer
July 02, 2012 08:30 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., July 2, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Decision in Teva Patent Litigation
June 22, 2012 21:02 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., June 22, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...